OncoShield directly targets MYB, HDAC2, and FOXA2 downregulation through epigenetic modulation, initiating the non-destructive reprogramming of cancer cells into a normal-like state, as demonstrated by KAIST. It leverages Phytoverse ingredients known for their effects on transcription factors and histone modifications.
Ingredients and Mechanisms:
· Curcumin: Inhibits HDAC2 by reducing its activity and expression, as noted in studies showing curcumin’s ability to restore tumor suppressor gene expression in cancer cells. Curcumin also suppresses NF-κB, which can indirectly reduce MYB-driven proliferation by modulating upstream pathways.
· EGCG : Modulates transcription factor activity and epigenetics, potentially downregulating FOXA2 by inhibiting its promoter activity, as seen in studies on gastrointestinal cancers. EGCG also inhibits HDAC activity, supporting HDAC2 suppression.
· Sulforaphane: Inhibits HDACs (including HDAC2) and activates Nrf2, creating an epigenetic environment that favors gene silencing of oncogenic drivers like MYB. Sulforaphane’s DNMT-inhibitory activity further supports epigenetic reprogramming.
· Genistein: Downregulates FOXA2 by targeting upstream pathways like PI3K/AKT, which FOXA2 interacts with to maintain cancer cell identity. Genistein also has mild HDAC inhibitory effects.
· Quercetin: Reduces MYB expression by inhibiting upstream regulators like c-Myc and supports HDAC inhibition, enhancing the epigenetic reset of cancer cells.
